Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 365.00 360.00 370.00 365.00 365.00 365.00 7,855 07:30:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 72.1 5.2 3.8 95.5 246

Eco Animal Health Share Discussion Threads

Showing 1201 to 1223 of 1250 messages
Chat Pages: 50  49  48  47  46  45  44  43  42  41  40  39  Older
It's infuriating how many people feel entitled to being spoon-fed :-)
It's infuriating why they can't give a number, even a range, this late in the financial year.And keep everyone guessing by the very vague "exceeding expectations"
Slight disappointment that there was no statement accompanying the recent AGM has certainly been blown away by this morning’s announcement that trading is significantly ahead of expectations and by the mkt response. Excellent.
We're both wrong, foxman, me more than you. I got the day wrong - the AGM is today - and you got the time wrong. It was at 2,00 p.m. The share price has nudged up since. Actually 4 nudges up so far, suggesting that something good was said to the few who listened in.
AGM today at 1.30pm
AGM tomorrow. I'm hoping there might be a positive statement accompanying it.
I have been going through both the recently published AR and the interims to see if I should increase my holding. I think I will stay where I am for now but would appreciate comments from you all as to where I have misunderstood. One big reason for me not buying more is I am having difficulty in understanding the company and one reason for that is that they do not appear to bother with IR for their retail investors. I take the point that it appears unlikely that they will need to do a fund raise in the immediate future and that those holding over 3% have a combined 65% share holding-ie retail investors are less important than in some other companies. That said they could have been more welcoming in their AGM like for example CWR and ITM or at the very least have done an Investor Meets Company type operation. I should add that the Finances seem better managed than in the past. It was surprising to read n page 126 of the AR that over an extended period an ex Director had helped herself to £300k+ without it being picked by internal or external auditors. Also, a bit disorientating to see that in the two years to March 2020 they paid out £18m in dividends and then we read in the latest interims they had to cut back on their R&D programme as they had insufficient cash. Suggests that perhaps a,lack, in the past, of long term strategic financial planning. What is welcome that there is now more transparency as to where the cash is i.e., China or non China than we seem to have had in the past. It is of course great that consolidated net cash grew from £9.8m at end March 2020 to £12.9m at end September 2020. However, that was due to cash balances of the Chinese company growing from £5.3m to £9.7m and cash balances ex China decreasing from £4.5m to £3.2m. The interims recognize that this cash balance in China-51% owned by EAH- gets transferred by dividends, as one would expect. It would be interesting to know when the next dividend will be paid. My reading of Pages 105/7 of the AR is that EAH would have got £1.6m and £0.97m in FY 2018/19 and 19/20 respectively…but please check that. Let’s hope that this next dividend is going to be higher. My reading of page 106 of the AR which shows a decline in 2020 over 2019 in plant and equipment of the Chinese JV is that the new factory in China is not owned by the JV but rather one assumes by a 100% owned EAH company…is that how you understand it? Begs the question to me is how they realize their factory investment in pounds sterling. All in all, I can well understand why they are not paying a dividend and I go on the basis that any dividend for this FY will be token. I note that the overdraft facility reported on Page 115 of the AR was new. I admit I am surprised that this facility repayable on demand is secured with what would appear to be a highish margin of 1.8%. All seems rather odd to me and suggests that the bank not all that comfortable. Page 116 tells us that the weighted average incremental borrowing rate for lease finance is a, to me, high 7.1%, I was interested to read page 87 of the AR with its good table of in which geographic markets they make their Ebitda. Interesting to see that in the year to 3/20 S and SE Asia far more profitable than China and Japan as regards adjusted ebitda to revenue from external customers and total assets but guess the picture will be different this FY
Well, there’s certainly strong buying again this morning and next to nothing being sold.
500p in sight.
city chappy
I'm still going through things but at current understanding it seems a lot of EPS fall/restatement is due to the need to charge early stage R&D to the P&L rather than capitalising it. If you reverse that you get an adjusted EPS of 16.15p for 2020 and 19.37 for 2019. Doing similar for ROCE makes that more realistic too. Obviously it's not necessarily ideal just to strip it all out but it does help see what's going on. Still need to go through a lot more but given ASF was raging through that period, it's not looking all that bad at all. Fingers crossed all this hefty R&D investment delivers some cracking new products too.
41000 shares just bought - somebody's keen. They're not alone though, by a long way. High volume of, mainly, purchases today.
Cerrito have you requested Investormeetcompany to approach the company? The more of us that do must increase the chances of it happening.
The debt jumped out at me too - it's in current liability though so isn't that they've taken on any long terms loans. That would have been a little bizarre given how cash generative it is. Was hoping that there may be an investor call too, particularly in light of the delays, etc. R&D was still a mighty 10% of revenue despite the caution when covid broke. The comments about large chunks of that having to be charged immediately to the P&L due to being early stage stand out too. That means EPS and ROCE need quite significant upwards adjustment to be put in true context. My dilemma if it re-rates again when FY21 ends in March is the quite hefty weighting it could start to have in my portfolio!
Encouraging news this morning and a really good forward outlook. Even after the opening rise in the sp, there’s still plenty more to go for.
I am disappointed that there is no indication that they are going to have a session for private investors - either an Investor meets company type event or a participatory AGM that CWR and ITM both successfully had.
Good stuff in the interims which is no surprise given the TU's and what ANP and Genus have told us. . That said my hand was hovering over the buy button till I saw the news of no dividend. Good that they spelt out the proportion of cash held in China. I note their comment on dividends from China and also the dividends due under current liabilities which I assume are the dividends due to the Chinese partner. Also note that for reasons not explained that the cash flow statement tells us they increased borrowing by £2m.
Interesting commentary on palm oil and soybeans prices on a trading data page I use for overview... "Also, China is buying increasing amounts of soybeans, palm’s top rival in the food and biodiesel industry, to power an aggressive expansion of the country’s hog industry." If only the shares weren't suspended!!
Yes good news. The China one not unexpected following Genus and good that in the first 9 months of the current FY the revenues were greater than 19/20. All that said, the way I read the comments on the audit is that there are going to be further delays and that the end Jan deadline will not be met for the finals and remember they are late on the interims.
Encouraging trading statement out this morning, with the key summary that “Group revenue and EBITDA for year ending 31 March 2021 expected to be significantly ahead of market expectations and prior year.”
Some positive news. Articles are saying that China's herd levels are almost back up to pre-ASF levels already. Numbers were at 90% of pre-ASF levels as of Nov 30. If the current trend continues, full recovery should happen in the first half of 2021.
I suspect that the pull back in share price is due to short term punters buying in anticipation of the results, who wanted/needed to sell rather than wait for January (or later). I'm long term.
A bit of the Boris Johnson syndrome here. The way I read the November 24 RNS they were pretty clear that we would have the results by year end. Now we are told that they believe that they will be ready in January. I guess the shares will be suspended till the interims -due by year end-are published unless they get a waiver for that. I currently see the suspension as being inconvenient rather than the end of the world. I first came a shareholder in July 23018 so do not have the historical perspective as others have as to how we have got in this mess.
This is what comes out of using Kreston Reeves LLP as an auditor of a complex group of this size. All looks a bit of a mess.
Chat Pages: 50  49  48  47  46  45  44  43  42  41  40  39  Older
ADVFN Advertorial
Your Recent History
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 21:36:59